title: Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients.
abstract: We assessed humoral and cytokine responses in monthly plasma samples from ALS patients who received glatiramer acetate (GA) immunization every day or every other week, or remained untreated (control) from a six-month phase II trial. Samples were evaluated by GA-specific ELISA assays for detection of combined immunoglobulin (Ig) classes (IgM,A,G), IgG alone, and IgG subclasses (IgG1, IgG2, IgG3, and IgG4). T-helper (Th) type 1 and 2 (Th1 and Th2) cytokine levels were determined by flow cytometric cytokine bead arrays. Fourteen of 21 GA-immunized patients produced anti-GA Ig responses. Those treated every day produced anti-GA responses within one month, while those treated every other week exhibited responses by month two. All anti-GA IgG subclass concentrations were increased in excess of 4.2-fold in plasma from treated patients, and anti-GA IgG1 comprised the majority of the humoral response. Mean plasma cytokine levels were statistically indistinguishable between treatment regimens; however, stratification by patient and time on study showed more prevalent trends in changes of Th1 or Th2 cytokine levels following GA treatment every other week or every day, respectively. These data show significant humoral responses and cytokine trends following GA immunization in ALS patients.
authors.affiliation: Center for Neurovirology and Neurodegenerative Disorders, University of Nebraska Medical Center, Omaha, NE 68198-5800, USA. rlmosley@unmc.edu
authors.forename: R Lee
authors.initials: RL
authors.lastname: Mosley
authors.forename: Paul H
authors.initials: PH
authors.lastname: Gordon
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Hasiak
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Van Wetering
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mitsumoto
authors.forename: Howard E
authors.initials: HE
authors.lastname: Gendelman
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D000704:Analysis of Variance; D000906:Antibodies / Q000097:blood* / Q000145:classification; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005434:Flow Cytometry / Q000379:methods; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000276:immunology* / Q000627:therapeutic use; D010455:Peptides / Q000276:immunology* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000906:Antibodies; D016207:Cytokines; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate